Takenobu Ohashi1, Yuko Suzuki2, Toshiyuki Yamamoto1. Show Affiliations » 1. Department of Dermatology, Fukushima Medical University, Fukushima, Japan. 2. Department of Blood Transfusion and Transplantation Immunology, Fukushima Medical University, Fukushima, Japan.
Abstract
Entities: Disease Species
Mesh： See more » Adalimumab/administration & dosageAdalimumab/adverse effectsAdalimumab/therapeutic useAdultAntirheumatic Agents/administration & dosageAntirheumatic Agents/adverse effectsAntirheumatic Agents/therapeutic useArthritis, Psoriatic/diagnostic imagingArthritis, Psoriatic/drug therapyArthritis, Psoriatic/pathologyBetamethasone/administration & dosageBetamethasone/analogs & derivativesBetamethasone/therapeutic useBiological Products/administration & dosageBiological Products/therapeutic useBiopsyBone Marrow/pathologyFemaleFinger Joint/diagnostic imagingHumansInfliximab/administration & dosageInfliximab/therapeutic useMagnetic Resonance ImagingMiddle AgedOsteitis/diagnostic imagingOsteitis/drug therapyOsteitis/etiologyPsoriasis/complicationsPsoriasis/drug therapyRadionuclide ImagingSkin/pathologySternum/diagnostic imagingTechnetium/administration & dosageTreatment Outcome
Substances： See more » Antirheumatic AgentsBiological Productsbetamethasone butyrate propionateTechnetiumBetamethasoneInfliximabAdalimumab
Year: 2016 PMID： 27162198 DOI： 10.1111/1346-8138.13447
Source DB: PubMed Journal: J Dermatol ISSN： 0385-2407 Impact factor: 4.005